Radiation oncology leader Prajnan Das, M.D., shares selections for the top abstracts that will be presented by UT MD Anderson researchers at this year’s American Society for Radiation Oncology (ASTRO) Annual Meeting.

Albert Koong, M.D., Ph.D., was officially appointed UT MD Anderson's Chief Scientific Officer in June 2026. He discusses his career, passions and the future of cancer research.

After receiving a prostate cancer diagnosis, Bob Barnes chose UT MD Anderson for treatment. Today, the longtime community leader and chairman and CEO of IBC Bank–Austin combines his personal cancer connection with a passion for philanthropy, recently helping raise nearly $300,000 through a charity golf tournament to support UT MD Anderson’s mission.

The University of Texas MD Anderson Cancer Center today announced that Albert Koong, M.D., Ph.D., an internationally recognized physician-scientist, has been appointed chief scientific officer (CSO), ...

Cuproptosis is a recently defined form of regulated cell death (RCD) driven by copper-induced mitochondrial proteotoxic stress. Distinct from other RC…

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes u....

ATR/PKMYT1 coinhibition induces synthetic lethality in Rb1-deficient breast cancers, supporting biomarker-guided therapy.

An interest in process improvement projects and learning from others led radiation oncologist Shalin Shah, M.D., to help launch MD Anderson’s first academic journal, Advances in Cancer Education and Quality Improvement (ACE-QI).

Nature Reviews Cancer - In this Review, Mao et al. discuss the regulation and interplay of the metabolic cell death pathways ferroptosis, disulfidptosis and cuproptosis and explore how these...

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson's appointment process, our information page may be the best place to start.

After completing his radiation oncology residency at MD Anderson and joining the faculty, Vincent Bernard-Pagan, M.D., Ph.D., shares what he learned from his training and what sets MD Anderson apart for trainees.

Targeted radiation helps patients with kidney cancer delay systemic therapy 

The benefit of regional nodal irradiation in the treatment of breast cancer is well established for patients with pathologically positive axillary nodes, but whether it is also beneficial for patie...

Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss t...

Christopher Flowers, M.D., division head of Cancer Medicine and chair of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, will be honored with the Jamie Von Roenn Excellence in T...

PURPOSEThe EXTEND trial tested the hypothesis that adding comprehensive metastasis-directed therapy (MDT) to chemotherapy would improve progression-free survival (PFS) over chemotherapy alone among pa...

A method, RARE-seq, for sensitive detection of cell-free RNAs in blood is demonstrated to have diverse clinical applications including diagnosing and characterizing human cancers, and tracking respons...